 Ipilimumab
"Ipilimumab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anti-CTLA-4 ANTIGEN monoclonal antibody initially indicated for the treatment of certain types of metastatic MELANOMA. Its mode of actions may include blocking of CTLA-4 mediated inhibition of CYTOTOXIC T LYMPHOCYTES, allowing for more efficient destruction of target tumor cells.
| Descriptor ID |
D000074324
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.060.798 D12.776.124.790.651.114.224.060.798 D12.776.377.715.548.114.224.200.798
|
| Concept/Terms |
Ipilimumab- Ipilimumab
- Anti-CTLA-4 MAb Ipilimumab
- Anti CTLA 4 MAb Ipilimumab
- Ipilimumab, Anti-CTLA-4 MAb
|
Below are MeSH descriptors whose meaning is more general than "Ipilimumab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Ipilimumab [D12.776.124.486.485.114.224.060.798]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Ipilimumab [D12.776.124.790.651.114.224.060.798]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
- Ipilimumab [D12.776.377.715.548.114.224.200.798]
Below are MeSH descriptors whose meaning is more specific than "Ipilimumab".
This graph shows the total number of publications written about "Ipilimumab" by people in this website by year, and whether "Ipilimumab" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 0 | 1 | 1 | | 2014 | 0 | 1 | 1 | | 2016 | 1 | 1 | 2 | | 2017 | 3 | 0 | 3 | | 2018 | 3 | 0 | 3 | | 2019 | 1 | 3 | 4 | | 2020 | 1 | 2 | 3 | | 2021 | 1 | 4 | 5 | | 2022 | 1 | 0 | 1 | | 2023 | 0 | 5 | 5 | | 2024 | 0 | 1 | 1 | | 2025 | 2 | 1 | 3 | | 2026 | 1 | 3 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Ipilimumab" by people in Profiles.
-
Tasaki Y, Sato K, Hamamoto S, Sugiyama Y, Ikoma H, Kawase K, Suzuki H, Noda Y, Usami M, Tsubouchi Y, Kato R, Sakata T, Tomita M, Mimura Y, Nagai T, Unno R, Etani T, Naiki T, Yasui T, Furukawa-Hibi Y. Impact of Organ-Specific Severe Immune-Related Adverse Events on Long-Term Survival and Treatment Transitions in Metastatic Renal Cell Carcinoma: A 5-Year Multicenter Multistate Analysis. Cancer Med. 2026 Oct; 15(10):e72410.
-
Campbell KM, Chen DG, Bustami ZE, Naser Al Deen N, Medina E, Gonzalez CR, Maxey J, Thompson MA, Samorodnitsky S, Kuklinski LF, Perez Garcilazo I, Baselga-Carretero I, Vega-Crespo A, Chen JM, Elumalai R, Visitacion M, Schiemann R, Padron L, Chang C, Zelin AE, Chelluri SS, Boffo S, Kendra KL, Chmielowski B, Truong TG, Khushalani NI, Collichio F, Ikeguchi AP, Victor AI, Margolin KA, Johnson DB, Chen Y, Sosman JA, Patel SP, Hu-Lieskovan S, Moon J, Wells DK, Spencer CN, Bellasea S, Vanderwalde AM, Wu MC, Scumpia PO, Ribas A. Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti-CTLA-4 in Melanoma with Primary Resistance to Anti-PD-1. Cancer Discov. 2026 Sep 01; 16(9):1801-1818.
-
He K, Forde PM, Govindan R, Santoro A, Gettinger S, Borghaei H, Spira A, Chu Q, Zinner R, Schoenfeld AJ, Camidge DR, Spigel DR, Gurpide A, Juergens RA, Laurie SA, Cerra M, Spires T, Greenawalt DM, Rapoport I, Gainor JF. Fast Real-Time Assessment of Combination Therapies in Immuno-ONcology in patients with advanced non-small-cell lung cancer (FRACTION-Lung). ESMO Open. 2026 Mar; 11(3):106078.
-
Morris VK, Ciombor KK, Xiao L, Ochieng JK, Marmonti E, Polite B, Weinberg BA, Krauss JC, Hays J, Mukherjee S, Aranha O, Iqbal S, Shields T, Benson AB, Kazmi S, Lieu C, Hochster H, Whisenant J, Haymaker C, Eng C. NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal. J Clin Oncol. 2026 Feb 20; 44(6):497-507.
-
Lorigan P, Medina TM, Nyakas M, Rutten A, Feun LG, Cowey CL, Payne M, Hussain I, Kuzel T, O'Day S, Sheri A, Friedlander PA, Kumar S, Bergersen VS, Foss Ø, Ellingsen EB, Bjørheim J, Bechter OE. The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): A randomized open-label phase 2 study. Eur J Cancer. 2026 Jan 17; 233:116162.
-
Patel SP, Sheth RA, Davis C, Medina T. Combination Immunotherapy With Nivolumab Plus Ipilimumab in Melanoma of Unknown Primary. J Clin Oncol. 2025 03 10; 43(8):907-911.
-
Asby SC, Thompson LE, Goedken M, Lucia SM, Dominguez AT, Kar A, Pitts TM, Kiseljak-Vassiliades K, Lang J, Aleksunes LM, Joy MS. Pathological findings of immunotherapy-induced nephrotoxicity in a humanized immune system mouse model. Kidney Int. 2025 05; 107(5):930-934.
-
Chae YK, Othus M, Patel SP, Wilkinson KJ, Whitman-Purves EM, Lea J, Schallenkamp JM, Adra N, Appleman LJ, Alden M, Thomes Pepin J, Ellerton JA, Poklepovic A, Walter A, Rampurwala MM, Robinson WR, Kim HS, Chung LI, McLeod CM, Lopez G, Chen HX, Sharon E, Streicher H, Ryan CW, Blanke CD, Kurzrock R. SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer. Clin Cancer Res. 2024 12 16; 30(24):5593-5600.
-
Weiss ME, Perzia BM, Sinard JH, Tran TT, Maeng MM. Primary Treatment of Eyelid Conjunctival Melanoma with Immunotherapy: A Case Report. Ophthalmic Plast Reconstr Surg. 2025 Jan-Feb 01; 41(1):e12-e15.
-
VanderWalde A, Bellasea SL, Kendra KL, Khushalani NI, Campbell KM, Scumpia PO, Kuklinski LF, Collichio F, Sosman JA, Ikeguchi A, Victor AI, Truong TG, Chmielowski B, Portnoy DC, Chen Y, Margolin K, Bane C, Dasanu CA, Johnson DB, Eroglu Z, Chandra S, Medina E, Gonzalez CR, Baselga-Carretero I, Vega-Crespo A, Garcilazo IP, Sharon E, Hu-Lieskovan S, Patel SP, Grossmann KF, Moon J, Wu MC, Ribas A. Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial. Nat Med. 2023 09; 29(9):2278-2285.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|